Genetic testing firm 23andMe said on Monday it is reducing about 40%, or 200 employees, from its workforce and discontinuing ...

The therapeutic programs of 23andMe include an antibody that restores the ability of the immune system to kill cancer cells.

“We are taking these difficult but necessary actions as we restructure 23andMe and focus on the long-term success of our core ...

We remain deeply grateful to the patients, investigators and study staff for their participation in our clinical trials,” ...

However, 23andMe expects that these measures will eventually save them as much as $35 million. The company's CEO, Anne ...

23andMe, the genetics startup that has repeatedly captured the public imagination and then faced nearly fatal business ...

“We are taking these difficult but necessary actions as we restructure 23andMe and focus on the long-term success of our core consumer business and research partnerships,” said CEO Anne Wojcicki. The ...

However, they revealed a deep-seated disagreement with co-founder and CEO Anne Wojcicki's strategic vision for the company. In her first on-the-record interview with Fortune since the mass ...

On Tuesday, Wojcicki announced the new additions to 23andMe’s board: Andre Fernandez, a former CFO at WeWork, Inc., and NCR ...

Andre Fernandez, Jim Frankola and Mark Jensen will join the company's CEO Anne Wojcicki on the board. 23andMe appointed three ...

23andMe has appointed three new independent directors to its board following the mass resignation of all seven of its ...